Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1982001461 - HYBRIDOMES HUMAINS, PRECURSEURS ET PRODUITS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED IS:

1. A method for producing human-human hybridomas producing specific human monoclonal antibodies against a predefined determinant site which comprises:
fusing lymphoid cells immunized against a pre- defined determinant site with rapidly growing HAT sensitive non-Epstein-Barr virus transformed neoplastic lymphoid cell in a fusing medium at an approximately equivalent cell ratio to produce a cell mixture;
dividing into each of a plurality of wells a suf-ficient number of cells of said cell mixture to encourage growth and incubating said cells in a nutrient medium for a sufficient time to expand the number of viable cells in each well;
growing the cells in HAT medium to produce clones free of HAT sensitive cells; and
selecting for clones producing monoclonal antibodies for said predefined determinant, site.

2. A method according to Claim 1, wherein said neoplastic lymphoid cells are HAT sensitive myeloma cells which are grown in the presence of 8-azaguanine before fusing.

3. A method according to Claim 2, wherein said immunized lymphoid cells are derived from spleen.

4. A method according to Claim 2, wherein said immunized lymphoid cells are derived from peripheral blood.

5. A method according to Claim 1, wherein said HAT medium contains at least about 30i.u./ml of insulin.

6. A method according to Claims 1 or 2, wherein said neoplastic lymphoid cell is U-266 or a cell derived therefrom.

7. A method according to Claim 1, wherein said neoplastic lymphoid cells are HAT sensitive lymphoma cells, which are grown in the presence of 8-azaguanine before fusing.

8. A method according to Claim 7, wherein said immunized lymphoid cells are derived from spleen.

9. A method according to Claim 7, wherein said immunized lymphoid cells are derived from peripheral blood.

10. Human monoclonal antibodies derived from a human-human hybridoma.

11. Antibodies according to Claim 10, wherein said human-human hybridoma is derived from non-Epstein-Barr virus transformed neoplastic lymphoid cell fusion partners.

12. Antibodies according to Claim 11, wherein said human-human hybridoma is derived from a myeloma cell.

13. Antibodies according to Claim 11, wherein said human-human hybridoma is derived from a lymphoma cell.

OMPI

14. Human monoclonal antibodies according to any of Claims 10, 11, 12 or 13, wherein said antibodies specifically bind to an antigen.

15. Human monoclonal antibodies according to any of Claims 10, 11, 12 or 13, wherein said antibodies specifically bind to a hapten.

16. Human monoclonal antibodies according to any of Claims 10, 11, 12 or 13, wherein said antibodies are IgG.

17. Human monoclonal antibodies according to any of Claims 10, 11, 12 or 13, wherein said antibodies are IgM.

18. Human monoclonal antibodies accordint to any of Claims 10, 11, 12 or 13, wherein said antibodies are IgA.

OMFI

19. Myeloma cells of the U-266-AR1 strain or cells derived therefrom.

OMPI
ι S

20. Human hybridoma cells.

21. Human hybridoma cells derived from a myeloma cell fusion partner.

22. Hyman hybridoma cells derived from a lymphoma cell partner.

23. Cells according to Claim 21, wherein said HAT sensitive myeloma cells are 8-azaguanine resistant.

24. Cells according to Claim 20, 21 or 22 producing monoclonal antibodies to a hapten.

25. Cells according to Claim 20, 21 or 22 producing monoclonal antibodies to an antigen.

26. Cells according to Claim 20, 21 or 22 wherein said myeloma cells are derived from the U-266 strain.

OMPI

27. A method for treating a human host subject to an undesirable physiological response from contact with a predefined antigen, which comprises:
administering to said human host human' monoclonal antibodies specific for said antigen in an amount sufficient to diminish said undesirable response.

28. A method according to Claim 27, wherein said antigen is endogenous to a pathogen.

29. A method according to Claim 27, wherein said antigen is endogenous to a virus .

30. A method according to Claim 27, wherein said antigen is a surface antigen of a cell.

31. A method according to Claim 30, wherein said cell is a pathogen.

OMPI

32. A composition of matter consisting essentially of human IgG molecules characterized by being:
a) substantially free of incomplete IgG molecules;
b) homogeneous in chemical composition; and
c) specifically binding to a predefined determinant site.

O RE.

-. 33. A composition of matter according to Claim 32, wherein said determinant site is on a hapten.

34. A composition of matter according to Claim 32, wherein said determinant site is on an antigen.

OMPI

35. A composition of matter consisting essentially of human IgM molecules characterized by being:
a) substantially free of incomplete IgM molecules;
b) homogeneous in chemical composition; and
c) specifically binding to a predefined determinant site.

36. A composition of matter according to Claim 35, wherein said determinant site is on a hapten.

37. A composition of matter according to Claim 35, wherein said determinant site is on an antigen.

38. A composition of matter according to Claims 32 or 35, wherein said determinant site is on the surface of a tumor cell.

39. A composition of matter according to Claims 32 or 35, wherein said determinant site is on the surface of a pathogen.

40. A composition of matter according to Claims 32 or 35, wherein said determinant site is a part of a toxin.

41. A composition of matter consisting essentially of human IgA molecules characterized by being:
a) substantially free of incomplete IgA molecules;
b) homogeneous in chemical composition; and
c) specifically binding to a predefined determinant site.

OMPI